A Study To Investigate The Safety And Efficacy Of CP- 690,550 In Patients With Moderate And Severe Ulcerative Colitis.

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Pfizer
ClinicalTrials.gov Identifier:
NCT00787202
First received: November 6, 2008
Last updated: March 6, 2013
Last verified: March 2013
  Purpose

The hypothesis of the study is that at least one dose of CP 690 550 is superior to placebo (inactive drug) in inducing remission in patients with moderate to severe ulcerative colitis.


Condition Intervention Phase
Ulcerative Colitis
Drug: CP- 690 550
Other: placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Placebo Controlled, Double Blind, Parallel Group Multi-Center Study In Order To Investigate Safety And Efficacy Of CP- 690 550 In Subjects With Moderate To Severe Ulcerative Colitis.

Resource links provided by NLM:


Further study details as provided by Pfizer:

Primary Outcome Measures:
  • Percentage of Participants With Clinical Response [ Time Frame: Week 8 ] [ Designated as safety issue: No ]
    Clinical response was defined as a decrease from baseline in Mayo score of at least 3 points and at least 30 percent, with accompanying decrease in subscore for rectal bleeding of at least 1 point or absolute subscore for rectal bleeding of 0 or 1. Mayo score: instrument designed to measure disease activity of ulcerative colitis. Total score range: 0 to 12; higher score=more severe disease. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of flexible proctosigmoidoscopy and physician global assessment, each ranged from 0 to 3 (0=normal, 1=mild, 2=moderate, 3=severe).


Secondary Outcome Measures:
  • Percentage of Participants With Clinical Remission [ Time Frame: Week 8 ] [ Designated as safety issue: No ]
    Clinical remission was defined as a total Mayo score of 2 points or lower, with no individual subscore exceeding 1 point. Mayo score:instrument designed to measure disease activity of ulcerative colitis. Total score range: 0 to 12; higher score=more severe disease. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of flexible proctosigmoidoscopy and physician global assessment, each ranged from 0 to 3 (0=normal, 1=mild, 2=moderate, 3=severe).

  • Percentage of Participants With Endoscopic Response [ Time Frame: Week 8 ] [ Designated as safety issue: No ]
    Endoscopic response was defined as decrease from baseline in the findings of the flexible proctosigmoidoscopy subscore of the Mayo score at least 1 point. Mayo score: instrument designed to measure disease activity of ulcerative colitis. Total score range: 0 to 12; higher score=more severe disease. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of flexible proctosigmoidoscopy and physician global assessment, each ranged from 0 to 3 (0=normal, 1=mild, 2=moderate, 3=severe).

  • Percentage of Participants With Endoscopic Remission [ Time Frame: Week 8 ] [ Designated as safety issue: No ]
    Endoscopic remission was defined as the findings of flexible proctosigmoidoscopy subscore of the Mayo score equals 0. Mayo score: instrument designed to measure disease activity of ulcerative colitis. Total score range: 0 to 12; higher score=more severe disease. It consisted of 4 subscores: stool frequency, rectal bleeding, findings of flexible proctosigmoidoscopy and physician global assessment, each ranged from 0 to 3 (0=normal, 1=mild, 2=moderate, 3=severe).

  • Change From Baseline in Partial Mayo Score at Week 2, 4, 8 and 12 [ Time Frame: Baseline, Week 2, 4, 8, 12 ] [ Designated as safety issue: No ]
    Partial Mayo score was ranged from 0 (normal or inactive disease) to 9 (severe disease) and calculated as the sum of 3 subscores: stool frequency, rectal bleeding and physician's global assessment, each ranged from 0 to 3 (0=normal, 1=mild, 2=moderate, 3=severe).

  • Change From Baseline in Total Inflammatory Bowel Disease Questionnaire (IBDQ) Score at Week 8 [ Time Frame: Baseline, Week 8 ] [ Designated as safety issue: No ]
    IBDQ: Psychometrically validated patient reported outcome (PRO) instrument for measuring disease-specific quality of life (QOL) in participants with IBD. IBDQ consists of 32 items, each item score ranged from 1 (worst possible response) to 7 (best possible response). Total score is sum of each item score, ranged from 32 to 224 with higher score indicates better QOL. Positive change in total score indicated improvement in QOL.

  • Change From Baseline in Level of C-Reactive Protein (CRP) at Week 4 and 8 [ Time Frame: Baseline, Week 4, 8 ] [ Designated as safety issue: No ]
    The test for CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. A decrease in the level of CRP indicates reduction in inflammation and therefore improvement.

  • Change From Baseline in Level of Fecal Calprotectin at Week 2, 4, 8 and 12 [ Time Frame: Baseline, Week 2, 4, 8, 12 ] [ Designated as safety issue: No ]
    Fecal calprotectin is an inflammatory marker for the gastrointestinal tract and considered as a measurement of neutrophil migration to the gastrointestinal tract. Higher values indicate more serious inflammation.

  • Plasma Concentration of CP-690,550 [ Time Frame: 0.25, 0.5, 1, 2 hours post-dose on Day 1, 0 (pre-dose) and 1 hour post-dose on Week 2, Week 4, 0 (pre-dose), 0.25, 0.5, 1, 2 hours post-dose on Week 8 ] [ Designated as safety issue: No ]
    Summary statistics were calculated for each dose group using the nominal collection times and by setting concentration values below the lower limit of quantification (LLOQ) (LLOQ=0.1 nanogram per milliliter [ng/mL]) to zero.


Enrollment: 195
Study Start Date: December 2008
Study Completion Date: September 2010
Primary Completion Date: September 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 15 mg BID Drug: CP- 690 550
Administration via oral route twice daily for the duration of treatment
Experimental: 10 mg BID Drug: CP- 690 550
Administration via oral route twice daily for the duration of treatment
Experimental: 3 mg BID Drug: CP- 690 550
Administration via oral route twice daily for the duration of treatment
Experimental: 0.5 mg BID Drug: CP- 690 550
Administration via oral route twice daily for the duration of treatment
Placebo Comparator: Placebo Other: placebo
Administration via oral route twice daily for the duration of treatment

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients must be at least 18 years of age at screening
  • Males and female patients with clinical diagnosis of ulcerative colitis ≥3 months prior to entry into the study.
  • Male and female patients with active currently moderate to severe ulcerative colitis defined by Mayo score of ≥6
  • Patients with endoscopic sub-score of ≥2 on the Mayo score determined within 7 days of baseline.

Exclusion Criteria:

  • Diagnosis of Crohn's disease or diagnosis of indeterminate colitis
  • Treatment naive subjects who have not had previous exposure to treatment for ulcerative colitis
  • Patients that are currently receiving immunosuppressants, anti-TNFα therapy or interferon
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00787202

  Hide Study Locations
Locations
Belgium
Pfizer Investigational Site
Antwerpen, Belgium, 2020
Pfizer Investigational Site
Gent, Belgium, 9000
Pfizer Investigational Site
Leuven, Belgium, 3000
Brazil
Pfizer Investigational Site
Porto Alegre, RS, Brazil, 90610-000
Pfizer Investigational Site
Sao Paulo, SP, Brazil, 01244-030
Pfizer Investigational Site
São Paulo, SP, Brazil, 05651-901
Chile
Pfizer Investigational Site
Independencia, Santiago RM, Chile, 8380456
Pfizer Investigational Site
Independencia, Santiago, Chile, 8380418
Pfizer Investigational Site
Vina del Mar, Chile, 2570017
Czech Republic
Pfizer Investigational Site
Hradec Kralove, Czech Republic, 50012
Pfizer Investigational Site
Olomouc, Czech Republic, 775 20
Pfizer Investigational Site
Usti n. Labem, Czech Republic, 401 13
Pfizer Investigational Site
Usti nad Labem, Czech Republic, 401 13
Denmark
Pfizer Investigational Site
Aalborg, Denmark, 9100
Pfizer Investigational Site
Aarhus C, Denmark, 8000
France
Pfizer Investigational Site
Bordeaux cedex, France, 33075
Pfizer Investigational Site
Lille Cedex, France, 59037
Pfizer Investigational Site
Marseille cedex 20, France, 13915
Pfizer Investigational Site
Nantes CEDEX 1, France, 44093
Hungary
Pfizer Investigational Site
Bekescsaba, Hungary, 5600
Pfizer Investigational Site
Budapest, Hungary, 1135
Pfizer Investigational Site
Budapest, Hungary, 1125
Pfizer Investigational Site
Debrecen, Hungary, 4004
Pfizer Investigational Site
Gyor, Hungary, 9023
Pfizer Investigational Site
Gyula, Hungary, 5701
Pfizer Investigational Site
Kaposvar, Hungary, 7400
Pfizer Investigational Site
Miskolc, Hungary, 3529
Pfizer Investigational Site
Mosonmagyarovar, Hungary, 9200
Pfizer Investigational Site
Szeged, Hungary, 6720
Pfizer Investigational Site
Szekszard, Hungary, 7100
Pfizer Investigational Site
Szentes, Hungary, 6600
Israel
Pfizer Investigational Site
Haifa, Israel, 31096
Pfizer Investigational Site
Petah-tikva, Israel, 49100
Pfizer Investigational Site
Tel Aviv, Israel, 64239
Italy
Pfizer Investigational Site
Bologna, Italy, 40138
Pfizer Investigational Site
Roma, Italy, 00152
Mexico
Pfizer Investigational Site
Delegacion Benito Juarez, Mexico DF, Mexico, 03300
Pfizer Investigational Site
Tlalpan, Mexico DF, Mexico, 14000
Netherlands
Pfizer Investigational Site
Amsterdam, NH, Netherlands, 1081 HV
Poland
Pfizer Investigational Site
Bydgoszcz, Poland, 85-168
Pfizer Investigational Site
Lodz, Poland, 90-153
Pfizer Investigational Site
Wroclaw, Poland, 50-556
Slovakia
Pfizer Investigational Site
Bratislava, Slovakia, 811 07
Pfizer Investigational Site
Bratislava, Slovakia, 826 06
Pfizer Investigational Site
Nitra, Slovakia, 94901
South Africa
Pfizer Investigational Site
Overport, Durban, South Africa, 4091
Pfizer Investigational Site
Johannesburg, Gauteng, South Africa, 2193
Pfizer Investigational Site
Durban, Kwa-Zulu Natal, South Africa, 4001
Pfizer Investigational Site
Claremont, Western Cape, South Africa, 7708
Pfizer Investigational Site
Durbanville, Western Cape, South Africa, 7550
Spain
Pfizer Investigational Site
L'hospitalet de Llobregat, Barcelona, Spain, 08907
Pfizer Investigational Site
Majadahonda, Madrid, Spain, 28222
Pfizer Investigational Site
Barcelona, Spain, 08036
Sweden
Pfizer Investigational Site
Umea, Sweden, 901 85
Pfizer Investigational Site
Vaxjo, Sweden, 351 85
United Kingdom
Pfizer Investigational Site
Bristol, United Kingdom, BS2 8HW
Pfizer Investigational Site
Glasgow, United Kingdom, G11 6NT
Pfizer Investigational Site
Glasgow, United Kingdom, G4 0SS
Pfizer Investigational Site
Manchester, United Kingdom, M13 9WL
Sponsors and Collaborators
Pfizer
Investigators
Study Director: Pfizer CT.gov Call Center Pfizer
  More Information

Additional Information:
No publications provided by Pfizer

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Pfizer
ClinicalTrials.gov Identifier: NCT00787202     History of Changes
Other Study ID Numbers: A3921063
Study First Received: November 6, 2008
Results First Received: December 4, 2012
Last Updated: March 6, 2013
Health Authority: United Kingdom: Medicines and Healthcare Products Regulatory Agency

Keywords provided by Pfizer:
treatment of ulcerative colitis; CP 690 550

Additional relevant MeSH terms:
Colitis
Colitis, Ulcerative
Ulcer
Gastroenteritis
Gastrointestinal Diseases
Digestive System Diseases
Colonic Diseases
Intestinal Diseases
Inflammatory Bowel Diseases
Pathologic Processes

ClinicalTrials.gov processed this record on August 21, 2014